Trade Partners

DEVA, having one of the strongest product portfolios in the pharmaceutical industry, is working to locally manufacture and make available on a global scale products that address the needs in various therapeutic areas and differentiates itself from the others with its value added products and original molecules. The product portfolio includes approximately 600 products spanning 13 therapeutic areas from oncology/hematology to cardiology, respiratory system and ophthalmology. The top company of turkey.

We are strengthening our foothold in international markets every day, and rapidly moving toward becoming a brand of choice globally, in line with our growth strategy. We are contributing to lower the trade deficit in pharmaceuticals industry, therefore, it is our priority to increase our exports. Our efforts focused on foreign markets utilizing various business models, including distributorship, out-licensing and supply, exportation, contract manufacturing and co-development, picked up speed last year. As of yearend 2019, the number of our approvals in international markets reached 700 in 60 countries. With our Devatis brand, we accelerated our efforts in Germany and Switzerland, countries of reference in the pharmaceutical industry, while getting ready to take a first step into new markets. On the other hand, we evaluated new opportunities for collaboration on business development projects with several international companies.

In our time, where local manufacturing has become extremely important, as we are creating value for a long term and sustainable employment, and thus we contribute to our national economy. Besides our efforts to increase output capacity, we continue our new investments at full speed. As of yearend 2019, our output capacity has reached 578 million units, and we have become a partner of choice for multinationals who are leaders in their respective fields, with our diverse pharmaceutical forms and production operations in our US FDA and EU GMP approved world-class facilities. On this point, last year we signed contract manufacturing agreements with leading multinational companies, improving the efficiency of our powerful output capacity.

Square Pharmaceuticals Limited, the flagship company of Square Group, is holding the strong leadership position in the pharmaceutical industry of Bangladesh since 1985 and is now on its way to becoming a high performance global player.

SQUARE today symbolizes a name – a state of mind. But its journey to the growth and prosperity has been no bed of roses. From the inception in 1958, it has today burgeoned into one of the top line conglomerates in Bangladesh. Square Pharmaceuticals Ltd., the flagship company, is holding the strong leadership position in the pharmaceutical industry of Bangladesh since 1985 and is now on its way to becoming a high performance global player.

SQUARE Pharmaceuticals Limited is the largest pharmaceutical company in Bangladesh and it has been continuously in the 1st position among all national and multinational companies since 1985. It was established in 1958, converted into a public limited company in 1991 and listed with stock exchanges in 1995. The turnover of Square Pharma was BDT 50.87 Billion (US$ 609.18 million) with about 16.95% market share having a growth rate of about 10.85% (July 2018– June 2019).

Looking beyond the horizon

SQUARE Pharmaceuticals Limited has extended its range of services towards the highway of global market. It pioneered exports of medicines from Bangladesh in 1987 and has been exporting antibiotics and other pharmaceutical products. Present export market covers 42 countries. This extension in business and services has manifested the credibility of Square Pharmaceuticals Limited.

Zade Global is part of the Helvacizade Group, a family-owned company that has been providing superior expertise and innovation in food, health and nutrition for every stage of life for more than 130 years. Zade Global is a leading producer of functional food, edible oils and pharmaceutical products in Europe, including its award-winning Zade Vital nutraceuticals and cosmeceuticals.

Zade Global operates in the fertile regions of Europe, the Mediterranean and Anatolia—benefiting from the regions’ rich soil, as well as the sun and waters of the Mediterranean, Aegean and Black Seas. Zade Global products are distributed in 85 countries.

Zade Global’s U.S. headquarters is based in Chicago. Zade Global, based in Konya, Turkey, is one of the country’s top businesses and is Europe’s largest softgel capsule manufacturing facility, producing 1 billion nutritional softgel capsules per year. Zade Global also is a leading supplier of branded products, retail, personal care and beauty to many international companies in the fields of food, pharmaceutical and raw materials.

have a distribution of infusion inside of the country in Kabul

Jan Pharma Limited was incorporated in February 2017 and commenced commercial production of intravenous solutions in September 2018 at its factory in Kabul, Afghanistan JPL’s current activities are mainly focused on the manufacturing of I.V. Solutions and marketing them effectively to remain in the lead both in quality and quantity. JPL’s is providing international quality solutions and medicines at the doorsteps of Doctors, Hospitals, and Pharmacies the medical profession in Afghanistan.